Shwetal Mehta
Overview
Explore the profile of Shwetal Mehta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blomquist M, Eghlimi R, Beniwal A, Grief D, Nascari D, Inge L, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892466
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with few effective treatments. EGFR alterations, including expression of the truncated variant EGFRvIII, are among the most frequent...
2.
Johnson K, Tien A, Jiang J, McNamara J, Chang Y, Montgomery C, et al.
medRxiv
. 2024 Jun;
PMID: 38883740
Outcomes for adult patients with a high-grade glioma continue to be dismal and new treatment paradigms are urgently needed. To optimize the opportunity for discovery, we performed a phase 0/1...
3.
Lo Cascio C, Margaryan T, Luna-Melendez E, McNamara J, White C, Knight W, et al.
JCI Insight
. 2023 Nov;
8(22).
PMID: 37991020
Histone deacetylase (HDAC) inhibitors have garnered considerable interest for the treatment of adult and pediatric malignant brain tumors. However, owing to their broad-spectrum nature and inability to effectively penetrate the...
4.
Chen P, Scarpelli M, Healey D, Mehta S, Quarles C
Front Oncol
. 2023 Oct;
13:1248249.
PMID: 37810983
Background: [F]fluciclovine amino acid PET has shown promise for detecting brain tumor regions undetected on conventional anatomic MRI scans. However, it remains unclear which of these modalities provides a better...
5.
Belykh E, Bardonova L, Abramov I, Byvaltsev V, Kerymbayev T, Yu K, et al.
Front Oncol
. 2023 Jun;
13:1156812.
PMID: 37287908
Introduction: Surgical resection remains the first-line treatment for gliomas. Several fluorescent dyes are currently in use to augment intraoperative tumor visualization, but information on their comparative effectiveness is lacking. We...
6.
Yoo W, Kim S, Garcia M, Mehta S, Sanai N
BMC Med Res Methodol
. 2022 Dec;
22(1):327.
PMID: 36550391
Background: Due to economical and ethical reasons, the two-stage designs have been widely used for Phase 2 single-arm trials in oncology because the designs allow us to stop the trial...
7.
Adjei-Sowah E, OConnor S, Veldhuizen J, Lo Cascio C, Plaisier C, Mehta S, et al.
Adv Sci (Weinh)
. 2022 May;
9(21):e2201436.
PMID: 35619544
The perivascular niche (PVN) is a glioblastoma tumor microenvironment (TME) that serves as a safe haven for glioma stem cells (GSCs), and acts as a reservoir that inevitably leads to...
8.
Scarpelli M, Healey D, Mehta S, Quarles C
Front Oncol
. 2022 Feb;
12:829050.
PMID: 35174096
Introduction: Conventional methods of imaging brain tumors fail to assess metabolically active tumor regions, which limits their capabilities for tumor detection, localization, and response assessment. Positron emission tomography (PET) with...
9.
Heffernan J, McNamara J, Vernon B, Mehta S, Sirianni R
Biomater Sci
. 2022 Jan;
10(3):819-833.
PMID: 34994746
Glioblastoma (GBM) brain tumors contain a subpopulation of self-renewing multipotent Glioblastoma stem-like cells (GSCs) that are believed to drive the near inevitable recurrence of GBM. We previously engineered temperature responsive...
10.
Han C, Lang M, Nguyen C, Luna Melendez E, Mehta S, Turner G, et al.
J Neurosurg
. 2021 Nov;
137(1):163-174.
PMID: 34740197
Objective: Hereditary hemorrhagic telangiectasia is the only condition associated with multiple inherited brain arteriovenous malformations (AVMs). Therefore, a mouse model was developed with a genetics-based approach that conditionally deleted the...